Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine

Vaccine

Volumn 29, Issue 28, 2011, Pages 4623-4631

  Tifrea, Delia F ^a   Sun, Guifeng ^a   Pal, Sukumar ^a   Zardeneta, Gustavo ^a   Cocco, Melanie J ^b   Popot, Jean Luc ^c   De la Maza, Luis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CNRS   (France)

Author keywords

Amphipols; Chlamydia; Detergents; Major outer membrane protein; Thermal stability; Vaccine protection

Indexed keywords

AMPHIPATHIC POLYMER; OUTER MEMBRANE PROTEIN; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; INFECTION PREVENTION; LUNG WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERMOSTABILITY; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CIRCULAR DICHROISM; DETERGENTS; FEMALE; LUNG; MICE; MICE, INBRED BALB C; POLYMERS; PROPYLAMINES; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINATION;

EID: 79958151390     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.065     Document Type: Article

References (62)

1. Chlamydia screening among sexually active young female enrolees of health plans - United States, 2000-2007. MMWR Morb Mortal Wkly Rep 2009;58(April (14)):362-5.
2. Miller W.C., Ford C.A., Morris M., Handcock M.S., Schmitz J.L., Hobbs M.M., et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004, 291(May (18)):2229-2236.
3. Schachter J., Dawson C. Human chlamydial infections 1978, PSG Publishing Co, Littleton.
4. Westrom L., Joesoef R., Reynolds G., Hagdu A., Thompson S.E. Pelvic inflammatory disease and fertility A cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992, 19(July-August (4)):185-192.
5. Beem M.O., Saxon E.M. Respiratory-tract colonization and a distinctive pneumonia syndrome in infants infected with Chlamydia trachomatis. N Engl J Med 1977, 296(February (6)):306-310.
6. Stutman H.R., Rettig P.J., Reyes S. Chlamydia trachomatis as a cause of pneumonitis and pleural effusion. J Pediatr 1984, 104(April (4)):588-591.
7. Arth C., Von Schmidt B., Grossman M., Schachter J. Chlamydial pneumonitis. J Pediatr 1978, 93(September (3)):447-449.
8. Tack K.J., Peterson P.K., Rasp F.L., O'Leary M., Hanto D., Simmons R.L., et al. Isolation of Chlamydia trachomatis from the lower respiratory tract of adults. Lancet 1980, 1(January (8160)):116-120.
9. Grayston J.T., Wang S. New knowledge of chlamydiae and the diseases they cause. J Infect Dis 1975, 132(July (1)):87-105.
10. Grayston J.T. Symposium on trachoma. Biology of the virus. Invest Ophthalmol 1963, 2(October):460-470.
11. Schachter J., Dawson C.R. Elimination of blinding trachoma. Curr Opin Infect Dis 2002, 15(October (5)):491-495.
12. Ward H., Martin I., Macdonald N., Alexander S., Simms I., Fenton K., et al. Lymphogranuloma venereum in the United Kingdom. Clin Infect Dis 2007, 44(January (1)):26-32.
13. Stamm W. Chlamydia trachomatis infections of the adult. Sexually transmitted diseases 2008, 575-593. McGrawHill Book Co, New York. K.K.P.S. Holmes, W.E. Stamm, P. Piot, J.W. Wasserheit, L. Corey, M.S. Cohen, D.H. Watts (Eds.).
14. Grayston J.T., Wang S.P. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis 1978, 5(April-June (2)):73-77.
15. Morrison R.P., Belland R.J., Lyng K., Caldwell H.D. Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein. J Exp Med 1989, 170(October (4)):1271-1283.
16. Sun G., Pal S., Sarcon A.K., Kim S., Sugawara E., Nikaido H., et al. Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J Bacteriol 2007, 189(September (17)):6222-6235.
17. Nikaido H. Porins and specific channels of bacterial outer membranes. Mol Microbiol 1992, 6(February (4)):435-442.
18. Stephens R.S., Sanchez-Pescador R., Wagar E.A., Inouye C., Urdea M.S. Diversity of Chlamydia trachomatis major outer membrane protein genes. J Bacteriol 1987, 169(September (9)):3879-3885.
19. Rodriguez-Maranon M.J., Bush R.M., Peterson E.M., Schirmer T., de la Maza L.M. Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia. Protein Sci 2002, 11(July (7)):1854-1861.
20. Pal S., Peterson E.M., de la Maza L.M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun 2005, 73(December (12)):8153-8160.
21. Pal S., Davis H.L., Peterson E.M., de la Maza L.M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun 2002, 70(September (9)):4812-4817.
22. Kari L., Whitmire W.M., Crane D.D., Reveneau N., Carlson J.H., Goheen M.M., et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol 2009, 182(June (12)):8063-8070.
23. Tribet C., Audebert R., Popot J.L. Amphipols: polymers that keep membrane proteins soluble in aqueous solutions. Proc Natl Acad Sci USA 1996, 93(December (26)):15047-15050.
24. Popot J.L., Berry E.A., Charvolin D., Creuzenet C., Ebel C., Engelman D.M., et al. Amphipols: polymeric surfactants for membrane biology research. Cell Mol Life Sci 2003, 60(August (8)):1559-1574.
25. Popot J.L. Amphipols, nanodiscs, and fluorinated surfactants: three nonconventional approaches to studying membrane proteins in aqueous solutions. Annu Rev Biochem 2010, 79(July):737-775.
26. Nigg C. An unidentified virus which produces pneumonia and systemic infection in mice. Science 1942, 95(January (2454)):49-50.
27. Caldwell H.D., Kromhout J., Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 1981, 31(March (3)):1161-1176.
28. Sun G., Pal S., Weiland J., Peterson E.M., de la Maza L.M. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 2009, 27(August (36)):5020-5025.
29. Pal S., Theodor I., Peterson E.M., de la Maza L.M. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect Immun 1997, 65(August (8)):3361-3369.
30. Yen T.Y., Pal S., de la Maza L.M. Characterization of the disulfide bonds and free cysteine residues of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Biochemistry 2005, 44(April (16)):6250-6256.
31. Gohon Y., Pavlov G., Timmins P., Tribet C., Popot J.L., Ebel C. Partial specific volume and solvent interactions of amphipol A8-35. Anal Biochem 2004, 334(November (2)):318-334.
32. Gohon Y., Giusti F., Prata C., Charvolin D., Timmins P., Ebel C., et al. Well-defined nanoparticles formed by hydrophobic assembly of a short and polydisperse random terpolymer, amphipol A8-35. Langmuir 2006, 22(January (3)):1281-1290.
33. Schagger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100kDa. Anal Biochem 1987, 166(November (2)):368-379.
34. Pal S., Fielder T.J., Peterson E.M., de la Maza L.M. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun 1994, 62(August (8)):3354-3362.
35. Peterson E.M., Zhong G.M., Carlson E., de la Maza L.M. Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect Immun 1988, 56(April (4)):885-891.
36. Cai S., He F., Samra H.S., de la Maza L.M., Bottazzi M.E., Joshi S.B., et al. Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Mol Pharm 2009, 6(September-October (5)):1553-1561.
37. Mattice W.L., Riser J.M., Clark D.S. Conformational properties of the complexes formed by proteins and sodium dodecyl sulfate. Biochemistry 1976, 15(September (19)):4264-4272.
38. Charvolin D., Perez J.B., Rouvière F., Giusti F., Bazzacco P., Abdine A., et al. The use of amphipols as universal molecular adapters to immobilize membrane proteins onto solid supports. Proc Natl Acad Sci USA 2009, 106(January (2)):405-410.
39. Quadros C. Preventing disease and protecting health 2004, Pan American Health Organization, Washington.
40. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47(August (3)):401-409.
41. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13(May (5)):552-559.
42. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440(April (7085)):808-812.
43. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7(March (3)):179-190.
44. Harandi A.M., Davies G., Olesen O.F. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 2009, 8(March (3)):293-298.
45. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21(June (Suppl 2)):S89-95.
46. Hui G.S., Hashimoto C.N. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int Immunopharmacol 2008, 8(July (7)):1012-1022.
47. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995, 92(December (25)):11553-11557.
48. Ionescu-Matiu I., Kennedy R.C., Sparrow J.T., Culwell A.R., Sanchez Y., Melnick J.L., et al. Epitopes associated with a synthetic hepatitis B surface antigen peptide. J Immunol 1983, 130(April (4)):1947-1952.
49. Zoonens M., Giusti F., Zito F., Popot J.L. Dynamics of membrane protein/amphipol association studied by Förster resonance energy transfer: implications for in vitro studies of amphipol-stabilized membrane proteins. Biochemistry 2007, 46(September (36)):10392-10404.
50. Tribet C., Diab C., Dahmane T., Zoonens M., Popot J.L., Winnik F.M. Thermodynamic characterization of the exchange of detergents and amphipols at the surfaces of integral membrane proteins. Langmuir 2009, 25(November (21)):12623-12634.
51. Rockey D.D., Wang J., Lei L., Zhong G. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines 2009, 8(October (10)):1365-1377.
52. Morrison R.P., Caldwell H.D. Immunity to murine chlamydial genital infection. Infect Immun 2002, 70(June (6)):2741-2751.
53. Brunham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005, 5(February (2)):149-161.
54. Morrison S.G., Morrison R.P. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol 2005, 175(December (11)):7536-7542.
55. Pal S., Bravo J., Peterson E.M., de la Maza L.M. Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Infect Immun 2008, 76(December (12)):5581-5587.
56. Pal S., Theodor I., Peterson E.M., de la Maza L.M. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine 1997, 15(April (5)):575-582.
57. Miller J., Williamson E.D., Lakey J.H., Pearce M.J., Jones S.M., Titball R.W. Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol Med Microbiol 1998, 21(July (3)):213-221.
58. Musson J.A., Morton M., Walker N., Harper H.M., McNeill H.V., Williamson E.D., et al. Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes. J Biol Chem 2006, 281(September (36)):26129-26135.
59. Hanada K., Yewdell J.W., Yang J.C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 2004, 427(January (6971)):252-256.
60. Warren E.H., Vigneron N.J., Gavin M.A., Coulie P.G., Stroobant V., Dalet A., et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 2006, 313(September (5792)):1444-1447.
61. Maric M., Arunachalam B., Phan U.T., Dong C., Garrett W.S., Cannon K.S., et al. Defective antigen processing in GILT-free mice. Science 2001, 294(November (5545)):1361-1365.
62. Singh R., Cresswell P. Defective cross-presentation of viral antigens in GILT-free mice. Science 2010, 328(June (5984)):1394-1398.